News|Articles|June 10, 2025

Daily Derm Times: June 9, 2025

Listen
0:00 / 0:00

Key Takeaways

  • Denifanstat shows promising phase 3 results for acne, indicating potential advancements in acne treatment.
  • Barzolvolimab, an anti-KIT antibody, rapidly reduces symptoms in antihistamine-refractory chronic spontaneous urticaria.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

The Rx Recap: June 1-7

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

The Weekly Roundup: June 2-6

In case you missed it, this week we had news about denifanstat's promising phase 3 results for acne, emerging therapies in lichen planus, initial insights from RAD 2025, and more.

Dermatology Times' Weekly Crossword: June 9, 2025

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Top 5 Articles of the Week: June 1-6

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine–refractory CSU.

Almirall Is First to Apply WHO-5 Well-Being Index in Dermatological Clinical Trial Endpoints

Almirall is pioneering a holistic approach in dermatology, emphasizing psychological well-being through the WHO-5 index in clinical trials.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME